Answers are grounded in this paper and cite their sources.
Intravenous recombinant hirudin may be a viable long-term anticoagulation strategy for LVAD patients complicated by heparin-induced thrombocytopenia.
We report on a 24 year old man with a Novacor left ventricular assist device (LVAD) who underwent long-term treatment with intravenous recombinant hirudin due to a heparin induced thrombocytopenia (HIT II) after suffering from an ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Tandler et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: